title: Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.
abstract: The selective vasopressin V2-receptor antagonist tolvaptan is eliminated almost exclusively by non-renal mechanisms. As renal impairment can influence the pharmacokinetics of drugs even when eliminated by non-renal mechanisms, we evaluated the effect of renal insufficiency on the pharmacokinetics/pharmacodynamics of tolvaptan. Thirty-seven patients were grouped by a 24-h creatinine clearance (CrCL) and evaluated for 48 h after a single 60 mg oral dose in the fasting state. Mean tolvaptan exposure was 90% higher in the under 30-ml/min group compared with the over 60-ml/min group with individual values significantly but negatively correlated with increasing baseline CrCL. There was a greater and more rapid increase in urine output and free water clearance in the over 60-ml/min compared with the renal impaired groups, but they returned to baseline more quickly. Serum sodium increased more rapidly in the over 60 as opposed to the under 30-ml/min group, but overall maximum increases were similar across groups. Small decreases in mean CrCL and small increases in mean serum creatinine/potassium were independent of baseline CrCL. The percent fractional free water clearance with respect to CrCL was significantly but negatively correlated with increasing baseline CrCL. No unexpected adverse events were reported. Thus, renal impairment attenuated the increase in 24-h urine volume and free water clearance caused by tolvaptan, consistent with decreased nephron function in renal impairment. The delay in serum sodium increase was consistent with the longer duration needed to excrete sufficient water to cause the increase.
authors.affiliation: Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland, USA.
authors.forename: Susan E
authors.initials: SE
authors.lastname: Shoaf
authors.affiliation: Clinical Management, Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland, USA.
authors.forename: Patricia
authors.initials: P
authors.lastname: Bricmont
authors.affiliation: Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland, USA.
authors.forename: Suresh
authors.initials: S
authors.lastname: Mallikaarjun
mesh_terms: D000284:Administration, Oral; D000368:Aged; D065092:Antidiuretic Hormone Receptor Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001552:Benzazepines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D051436:Renal Insufficiency, Chronic / Q000378:metabolism*; D000077602:Tolvaptan
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan
references.citation: J Clin Pharmacol. 2012 Sep;52(9):1388-98
references.pmid: 21960668
references.citation: N Engl J Med. 2006 Nov 16;355(20):2099-112
references.pmid: 17105757
references.citation: J Am Soc Nephrol. 2010 Apr;21(4):705-12
references.pmid: 20185637
references.citation: Am J Kidney Dis. 2011 May;57(5):692-9
references.pmid: 21333426
references.citation: J Cardiovasc Pharmacol. 2012 Apr;59(4):315-22
references.pmid: 22130104
references.citation: Br J Clin Pharmacol. 2010 Nov;70(5):703-12
references.pmid: 21039764
references.citation: Ann Intern Med. 2003 Jul 15;139(2):137-47
references.pmid: 12859163
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: J Am Soc Nephrol. 2010 Jun;21(6):898-910
references.pmid: 20150537
references.citation: Eur J Endocrinol. 2011 May;164(5):725-32
references.pmid: 21317283
references.citation: Eur J Clin Pharmacol. 2009 Aug;65(8):757-73
references.pmid: 19543887
references.citation: Kidney Int. 2011 Aug;80(3):295-301
references.pmid: 21544064
references.citation: Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S5-17
references.pmid: 22120090
references.citation: N Engl J Med. 2012 Dec 20;367(25):2407-18
references.pmid: 23121377
references.citation: Eur J Clin Pharmacol. 2012 Dec;68(12):1595-603
references.pmid: 22585285
references.citation: Int J Clin Pharmacol Ther. 2011 Jan;49(1):3-13
references.pmid: 21176719
references.citation: J Clin Pharmacol. 2007 Dec;47(12):1498-507
references.pmid: 17925589
references.citation: Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507
references.pmid: 21903984